A pharmacokinetic study of cyclosporin (Sandimmune®)

Clinical Drug Investigation

Volumn 13, Issue 1, 1997, Pages 23-36

  Primmett, Dennis R N ^a,b   Levine, Marc ^b   Wrishko, Rebecca ^a,b   Keown, Paul A ^a,b  

^a VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; PREDNISONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG EXPOSURE; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031028513     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199713010-00004     Document Type: Article

References (32)

1. Dossing M, Poulsen HE, Andreasen PB, et al. A simple method for determination of antipyrine clearance. Clin Pharmacol Ther 1982; 32: 392-6
2. Dossing M, Volund A, Poulsen HE. Optimal sampling times for minimum variance of clearance determination. Br J Clin Pharmacol 1983; 15: 231-5
3. Klompmaker IJ, Wierda JMKH, Sluiter WJ, et al. Pharmacokinetics of cyclosporine A after intravenous and oral administration in liver transplant patients measured with high performance liquid chromatography. Ther Drug Monit 1993; 15: 60-4
4. Kuhan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985; 40: 457-74
5. Grevel J. Significance of cyclosporine pharmacokinetics. Transplant Proc 1988; 20 Suppl. 2: 428-34
6. Newburger J, Kahan BD. Cyclosporine pharmacokinetics in man. Transplant Proc 1983; 15: 2413
7. Yee GC, Kennedy MS, Storb R, et al. Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients. Blood 1984; 64: 1377
8. Gupta SK, Manfro RC, Tomlanovich SJ, et al. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol 1990; 30: 643-53
9. Ptachcinski RJ, Venkataramanan R, Burckart GJ, et al. Dose-dependent absorption of cyclosporine. Drug Intell Clin Pharm 1985; 19: 450
10. Kahan BD, Ried M, Newburger J. Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 1983; 15: 446-53
11. Phillips TM, Karmi SA, Frantz SC, et al. Absorption profiles of renal allograft recipients receiving oral doses of cyclosporine: a pharmacokinetic study. Transplant Proc 1988; 20: 457-61
12. Lindholm A, Henricsson S, Lind M, et al. Intraindividual variability in the relative systemic availability of cyclosporine after oral dosing. Eur J Clin Pharmacol 1988; 34: 461-4
13. Lindholm A, Welsh M, Alton C, et al. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther 1992; 52: 359-71
14. Grevel J, Kutz K, Abisch E, et al. Evidence for zero-order absorption of cyclosporine A [abstract]. Br J Pharmacol 1986; 22: 220
15. Reymond JP, Steimer JL, Niederberger W. On the dose dependency of cyclosporine A absorption and disposition in healthy volunteers. J Pharmacokinet Biopharm 1988; 16: 331-53
16. Lindholm A. Review: factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991; 13: 465-77
17. Frey FJ, Horhen FF, Frey BM. Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation. Clin Pharmacol Ther 1988; 43: 55-62
18. Grevel J, Post BK, Kahan BD. Michaelis-Menten kinetics determine cyclosporine steady-state concentrations: a population analysis in kidney transplant patients. Clin Pharmacol Ther 1993; 53: 651-60
19. Nashan B, Bleck J, Wonigeit K, et al. Effect of the application form of cyclosporine on blood levels: comparison of oral solution and capsules. Transplant Proc 1988; 20[2]: 637-9
20. Zehnder C, Beveridge T, Nuesch E, et al. Cyclosporine A capsules: bioavailability and clinical acceptance in renal transplant patients. Transplant Proc 1988; 20 Suppl. 2: 641-3
21. Humbert H, Vernillet L, Cabiac MD, et al. Influence of different parameters for the monitoring of cyclosporine. Transplant Proc 1990; 22 (3): 1210-5
22. Reinherg A, Smolensky MH. Circadian changes of drug disposition in man. Clin Pharmacokinet 1982; 7: 401-20
23. Canafax D, Cipolle R, Hrushesky W, et al. The chrono-pharmacokinetics of cyclosporine and its metabolites in recipients of pancreas allografts. Transplant Proc 1988; 20 Suppl. 2: 471-7
24. Cipolle R, Canafax D, Rabatin, J, et al. Time-dependent disposition of cyclosporine after pancreas transplantation, and application of chronopharmacokinetics to improve immunosuppression. Pharmacotherapy 1988; 8: 47-51
25. Sabate I, Grino JM, Castalao AM, et al. Diurnal variations of cyclosporine and metabolites in renal transplant patients. Transplant Proc 1990; 22 (4): 1700-1
26. Scheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12
27. Kovarik JM, Mueller EA, Van Bree JB, et al. Cyclosporine pharmacokinetics and variability from a microemulsion formulation - a multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658-63
28. Levy G, Grant D. Potential for CsA-Neoral in organ transplantation. In: Kahan BD, editor. Cyclosporine, the ten-year experience. Norwalk Conn: Appleton & Lange. 1994: 2932-4
29. Kahan BD, Dunn J, Fitts C, et al. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant patients. In: Kahan BD, editor. Cyclosporine, the ten-year experience. Norwalk Conn: Appleton & Lange, 1994: 2940-3
30. Mikhail G, Eadon H, Leaver N, et al. Use of Neoral in heart transplant recipients. In: Kahan BD, editor. Cyclosporine, the ten-year experience. Norwalk Conn: Appleton & Lange, 1994: 2985-7
31. Fiocchi F, Mam-Prin F, Gamba A, et al. Pharmacokinetic profile of cyclosporine in long-term heart transplanted patients treated with a new oral formulation. Transplant Proc 1994; 26 (5): 2994-5
32. Holt DW, Mueller EA, Kovarik JM, et al. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine. In: Kahan BD, editor. Cyclosporine, the ten-year experience. Norwalk Conn: Appleton & Lange. 1994: 2935-9